Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trending Stock Alerts

IONS Stock - Ionis Pharmaceuticals Stock Trading


home / stock / ions

IONS IONS Quote IONS Short IONS News IONS Articles IONS Message Board

MWN AI Summary *

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) is a pioneering biopharmaceutical company focused on developing innovative therapies based on its proprietary antisense drug technology platform. Founded in 1989, Ionis specializes in treating various diseases, particularly genetic disorders, neurological illnesses, and cardiovascular conditions. The company's unique approach enables it to design RNA-targeted therapeutics that can modulate gene expression, offering a novel mechanism to address unmet medical needs.

As of October 2023, Ionis has made significant strides in its pipeline, with a diverse portfolio of products in various stages of development. Its most advanced product, Spinraza (nusinersen), is a groundbreaking treatment for spinal muscular atrophy (SMA) and was developed in partnership with Biogen. This collaboration has validated Ionis' technology and opened the door for further partnerships with major pharmaceutical companies.

Ionis is also focused on advancing its pipeline of investigational therapies, including treatments for conditions like amyloidosis, hypercholesterolemia, and Huntington's disease. Notable candidates include IONis TTR-LRx, a potential treatment for transthyretin amyloidosis, which has shown promising clinical results. The company’s collaboration with other biotech and pharmaceutical firms enhances its research capabilities and access to additional resources, amplifying its ability to bring new treatments to market.

In addition to its therapeutic innovations, Ionis is actively engaged in expanding its scientific knowledge and therapeutic applications, reflecting its commitment to addressing challenging diseases. Financially, the company maintains a robust balance sheet, supported by revenue from royalties and partnerships.

As the healthcare landscape continues to evolve, Ionis Pharmaceuticals remains positioned as a frontrunner in RNA-targeted therapeutics, with a strong commitment to innovation and patient-centric solutions. Its ongoing research and development endeavors promise to contribute significantly to the future of biopharmaceuticals.

MWN AI Analysis *

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) presents an intriguing investment opportunity within the biotechnology sector, primarily focused on RNA-targeted drug discovery and development. As of October 2023, the company's strategic partnerships and robust pipeline of drug candidates position it well for both short-term and long-term growth.

Reviewing Ionis's recent financial performance, the company has showcased a steady revenue stream through milestone payments and royalties from its collaboration with large pharmaceutical companies like Biogen and AstraZeneca. Their focus on treating rare genetic diseases, alongside advancing therapies for conditions such as neurological disorders and cardiovascular diseases, continues to expand its market reach.

Ionis's pipeline features several innovative products that have received considerable attention. The recent approval of therapies targeting conditions such as amyotrophic lateral sclerosis (ALS) highlights the company's capability to deliver groundbreaking treatments. Moreover, ongoing clinical trials for therapies addressing common conditions such as hyperlipidemia signify a strategic diversification in its product offerings, which could enhance future revenue potential.

From a valuation standpoint, Ionis's current price-to-earnings ratio reflects its strong growth prospects against the broader biotech sector. Investors should consider the volatility typically associated with biopharmaceutical stocks. Therefore, a balanced approach that accounts for potential risks, such as regulatory hurdles and competition in the RNA-targeted therapeutic landscape, is prudent.

In conclusion, for investors seeking exposure to the biotechnology sector, Ionis Pharmaceuticals presents a compelling case with its innovative pipeline and established partnerships. However, it is essential to remain vigilant with market sentiments and external market factors affecting biotechnology valuations. A well-timed entry during dips, combined with a long-term perspective, may yield substantial returns as the company continues to advance its offerings in the ever-evolving pharmaceutical landscape.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Quote | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)

Last:$41.34
Change Percent: 0.62%
Open:$41.52
Close:$41.34
High:$42.13
Low:$41.22
Volume:1,752,881
Last Trade Date Time:07/08/2025 03:40:44 pm

News | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)

  • Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight

    2025-06-29 13:04:38 ET Introduction Although this is my first article on Ionis Pharmaceuticals ( IONS ), I have followed the company for years. Ionis pioneered antisense oligonucleotide ( ASO ) technology, which is described in a Nature publication as “incredibly ...

    • June 29, 2025 01:04:38 pm

    • |
    • SeekingAlpha
    • |
      • IONS Stock
      • IONS Quote
      • IONS Short
      • IONS News
      • IONS Articles
      • IONS Message Board
  • New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

    New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA ® (nusinersen) Final results from the landmark NURTURE study high...

    • June 27, 2025 10:00:23 am

    • |
    • GlobeNewswire
    • |
      • IONS Stock
      • IONS Quote
      • IONS Short
      • IONS News
      • IONS Articles
      • IONS Message Board

Message Board Posts | Ionis Pharmaceuticals Inc. (NASDAQ:IONS)

Subject By Source When
whytestocks: $IONS News Article - Biogen and Alcyone Therapeutics Announce License and Collaboration whytestocks investorshangout 01/04/2023 9:00:53 PM
whytestocks: $IONS News Article - Ionis announces eplontersen met co-primary and secondary endpoints whytestocks investorshangout 06/21/2022 5:35:59 PM
whytestocks: $IONS News Article - Ionis partner Biogen announces that results from Phase 3 VALOR stu whytestocks investorshangout 06/03/2022 5:05:51 PM
whytestocks: $IONS News Article - Ionis to hold first quarter 2022 financial results webcast whytestocks investorshangout 04/20/2022 6:05:51 PM
whytestocks: $IONS News Article - Ionis announces positive data for ETESIAN Phase 2b study of antise whytestocks investorshangout 04/04/2022 12:25:53 PM

MWN AI FAQ **

What recent developments have impacted the stock performance of Ionis Pharmaceuticals Inc. IONS, and how do they align with the company's long-term growth strategy?

Recent advancements in Ionis Pharmaceuticals' drug pipeline, including positive clinical trial results and collaborations with larger pharmaceutical companies, have bolstered investor confidence and align with their long-term growth strategy of delivering innovative RNA-targeted therapies.

How does Ionis Pharmaceuticals Inc. IONS plan to navigate the competitive landscape in the biotechnology sector?

Ionis Pharmaceuticals Inc. plans to navigate the competitive biotechnology landscape by focusing on its proprietary antisense technology, expanding partnerships, advancing a robust pipeline of novel therapeutics, and leveraging strategic collaborations to enhance its market position.

What are the key financial metrics for Ionis Pharmaceuticals Inc. IONS that investors should monitor closely in the coming quarters?

Investors should closely monitor Ionis Pharmaceuticals' revenue growth, net income, research and development expenses, cash flow metrics, pipeline developments, and partnerships to gauge its financial health and future prospects.

How is Ionis Pharmaceuticals Inc. IONS addressing any regulatory challenges that could affect its drug pipeline and market position?

Ionis Pharmaceuticals Inc. is actively engaging with regulatory agencies to ensure compliance, streamline approval processes for its drug pipeline, and is focused on addressing any potential challenges through strategic partnerships and robust clinical data.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get IONS Alerts

News, Short Squeeze, Breakout and More Instantly...

Ionis Pharmaceuticals Inc. Company Name:

IONS Stock Symbol:

NASDAQ Market:

0.62% G/L:

$41.34 Last:

1,752,881 Volume:

$41.52 Open:

$41.34 Close:

Ionis Pharmaceuticals Inc. Website:

Ionis Pharmaceuticals Inc. Logo

Ad

Trending Stock Alerts
RECENT IONS NEWS
  • IONS - New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

    New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA ® (nusinersen) Final results from the landmark NURTURE study high...

  • IONS - Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

    – Investigational salanersen (ION306/BIIB115) developed using novel Ionis antisense chemistry with the potential to achieve high efficacy and once-yearly dosing – – Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substant...

  • IONS - Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

    Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA) Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neur...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get IONS Alerts

Get IONS Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1